New study aims to unravel nerve damage in rare blood cancer
NCT ID NCT07160270
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looks at why many people with Waldenström's macroglobulinemia, a rare blood cancer, develop nerve damage that can cause pain, numbness, and trouble moving. Researchers will examine 90 patients to find out how common this nerve damage is and what causes it. The goal is to help doctors diagnose the problem faster so they can start treatment early and prevent lasting harm.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to faster diagnosis of nerve damage in Waldenström's macroglobulinemia patients, helping doctors start treatment earlier to prevent permanent disability.
What could go wrong
This is an observational study, not a treatment trial. It may not directly improve outcomes, and findings may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL NEUROPATHIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Copenhagen Neuromuscular Center, Rigshospitalet Blegdamsvej.
RECRUITINGKøbenhavn Ø, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••